ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007.
暂无分享,去创建一个
M. Pfisterer | E. Braunwald | P. Serruys | S. Silber | M. Krucoff | E. Braunwald | M. Simoons | P. Jüni | A. Kastrati | S. Windecker | A. Farb | L. Wallentin | J. Fajadet | G. Guagliumi | H. Hillege | S. Carlier | P. Steg | G. Campo | E. Camenzind | W. Wijns | A. Gitt | B. Chevalier | S. James | M. Waliszewski | S. Kristensen | V. Legrand | S. Silber | J. Daemen | M. Rothman | A. Bagust | J. Bowen | J. De Schepper | H. Hillege | M. Lekehal | S. Kloth | E. Klasen | D. Allocco | A. Potgieter | L. Lenarz | C. Raveau-Landon | C. Dimario | G. Guagliumi | V. Legrand | J. Bowen | S. Hellbardt | D. Paunovic | G. Bos | I. Tariah | A. Aimonetti | A. Baczynska | M. Berenger | A. Boam | J. P. Calle | G. Di Bisceglie | H. Dobbels | J. Ghislain | R. ten Hoedt | C. Isaia | P. de Jong | F. Ni Mhullain | H. Nagai | A. Patteet | I. Purdy | S. Ternstrom | J. Van Wuytswinkel | S. Windecker | J. Schepper | G. Bisceglie | Peter Jüni | R. T. Hoedt | S. Kloth | E. Braunwald | S. James | M. Krucoff | J. V. Wuytswinkel | W. Wijns | M. Pfisterer | P. Jüni | Maarten L Simoons | Adrian Bagust | Carlo Dimario | Jean Fajadet | Anselm Gitt | Sabine Kloth | Matthias Pfisterer | Ibrahim Tariah | A Bagust | C Dimario | J Fajadet | A Gitt | P Jüni | S Kloth | S. D. Kristensen | M Pfisterer | M. Rothman | M L Simoons | I Tariah | A. Gitt | P. Jong | Sabine Kloth | J. M. Bowen | F. N. Mhullain | P. W. Serruys
[1] Frederic S. Resnic,et al. Long-Term Clinical Outcomes After Drug-Eluting and Bare-Metal Stenting in Massachusetts , 2008, Circulation.
[2] P. Serruys,et al. Four-year clinical follow-up of the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital registry. , 2008, The American journal of cardiology.
[3] Patrick W Serruys,et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial , 2008, The Lancet.
[4] P. Serruys,et al. Three-year follow-up of the ARTS-II# - sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[5] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[6] M. Pfisterer,et al. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitäts Trial (BASKET): an 18-month analysis , 2007, The Lancet.
[7] Marco Valgimigli,et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. , 2007, European heart journal.
[8] P. Fitzgerald,et al. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. , 2007, The American journal of cardiology.
[9] William Wijns,et al. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. , 2007, Circulation.
[10] Ron Goeree,et al. Effectiveness and safety of drug-eluting stents in Ontario. , 2007, The New England journal of medicine.
[11] Patrick W Serruys,et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. , 2007, Journal of the American College of Cardiology.
[12] Simon Wandel,et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.
[13] I. Palacios,et al. Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry. , 2007, European heart journal.
[14] S. Silber,et al. Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamente freisetzenden Koronarstents (DES) , 2007 .
[15] A. Kaltoft,et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. , 2007, Journal of the American College of Cardiology.
[16] P. Serruys,et al. Drug-Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug-Eluting Stents: Meaningful Advances or More of the Same? , 2007, Circulation.
[17] Raimund Erbel,et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial , 2007, The Lancet.
[18] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[19] P. Serruys,et al. Late Stent Thrombosis: A Nuisance in Both Bare Metal and Drug-Eluting Stents , 2007 .
[20] Johan Lindbäck,et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. , 2007, The New England journal of medicine.
[21] Marco Valgimigli,et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.
[22] S. Pocock,et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.
[23] P. Serruys,et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.
[24] Neville Kukreja,et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.
[25] P. Fitzgerald,et al. Randomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions: Clinical and Angiographic Results of the ENDEAVOR II Trial , 2006, Circulation.
[26] Patrick Hunziker,et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. , 2006, Journal of the American College of Cardiology.
[27] P. Serruys,et al. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry. , 2006, European heart journal.
[28] M. Briel,et al. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. , 2006, European heart journal.
[29] Michael Joner,et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.
[30] Matthew H Samore,et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. , 2006, Journal of the American College of Cardiology.
[31] I. Iakovou,et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.
[32] Antonio Colombo,et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. , 2005, European heart journal.
[33] Deepak L. Bhatt,et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. , 2005, Journal of the American College of Cardiology.
[34] Patrick W Serruys,et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2004, The Lancet.
[35] J. Popma,et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). , 2004, Journal of the American College of Cardiology.
[36] Charles L. Brown,et al. Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial: A Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at High Risk for Coronary Restenosis , 2004, Circulation.
[37] G. Stone,et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.
[38] S. Silber,et al. Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions , 2003, Circulation.
[39] Mary E. Russell,et al. TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions , 2003, Circulation.
[40] Patrick W. Serruys,et al. A randomized comparison of a sirolimus eluting stent with a standard stent for coronary revascularization , 2002 .
[41] Ousa,et al. A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .
[42] William Wijns,et al. A Cause for Concern , 2007 .